ASH 2021 | RESOLVE: Cord blood-derived Tregs in COVID-related ARDS
Douglas Gladstone, MD, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, presents findings from the randomized, double-blind, Phase I RESOLVE trial (NCT04468971) of CK0802, an allogeneic therapy consisting of cord blood-derived allogeneic T regulatory cells (Tregs), in patients with COVID19-induced acute respiratory distress syndrome (ARDS). 45 patients either received a dose of 100 million or 300 million cells and was compared to a placebo, with the primary endpoints being efficacy 28 days after treatment and safety. Patients receiving the 100 million cells dose reported a survival advantage at 28 days post-treatment. Dr Gladstone additionally describes the advantages of using cord blood-derived Tregs. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
